Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.53 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.53 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.53 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.53 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.53 |
| ▸ | GABRP | O00591 | 1/20 | 0.53 |
| ▸ | GABRD | O14764 | 1/20 | 0.53 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.53 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.53 |
| ▸ | GABRE | P78334 | 1/20 | 0.53 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.53 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.53 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.53 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.53 |
| ▸ | CCKBR | P32239 | 9/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8824647 | 1.00 | GABRA1 (0.53) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL8824650 | 1.00 | GABRA1 (0.53) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9530434 | 0.78 | GABRA1 (0.46) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL4414767 | 0.77 | CCKBR (0.47) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL30934892 | 0.77 | CCKBR (0.47) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL20098120 | 0.76 | CCKBR (0.38) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL17969884 | 0.76 | CCKBR (0.51) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL4988508 | 0.76 | CCKBR (0.44) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9866204 | 0.75 | CCKBR (0.47) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL652591 | 0.75 | CCKBR (0.50) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10865215-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200223867-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2020-07-16 | — | — | US | disclosed |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-5681833-A | ADMINSTERING FOR TREATMENT OF PEPTIC ULCER | MERCK, SHARP & DOHME LTD. (GB) | 1997-10-28 | — | — | US | disclosed |
| EP-0636123-A1 | 3-UREIDO SUBSTITUTED BENZODIAZEPIN-2-ONES HAVING CHOLECYSTOKININ AND/OR GASTRIN ANTAGONISTIC ACTIVITY AND THEIR USE IN THERAPY | MERCK SHARP & DOHME LTD. (GB) | 1995-02-01 | — | — | EP | disclosed |
| WO-1993019052-A1 | 3-UREIDO SUBSTITUTED BENZODIAZEPIN-2-ONES HAVING CHOLECYSTOKININ AND/OR GASTRIN ANTAGONISTIC ACTIVITY AND THEIR USE IN THERAPY | MERCK SHARP & DOHME LIMITED (GB) | 1993-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865215-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | GABRA1 2/4885GABRG2 22/4885GABRB3 14/4885 |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | SERPINB1, FURIN, HIF1AN | GABRA1 2263/4885GABRG2 2776/4885GABRB3 2165/4885 |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | GABRA1 2/4885GABRG2 22/4885GABRB3 14/4885 |
| US-20200223867-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | GABRA1 2/4885GABRG2 22/4885GABRB3 14/4885 |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | GABRA1 2263/4885GABRG2 2776/4885GABRB3 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.